PL2328893T3 - Związki triazolowe modulujące aktywność Hsp90 - Google Patents

Związki triazolowe modulujące aktywność Hsp90

Info

Publication number
PL2328893T3
PL2328893T3 PL09791292T PL09791292T PL2328893T3 PL 2328893 T3 PL2328893 T3 PL 2328893T3 PL 09791292 T PL09791292 T PL 09791292T PL 09791292 T PL09791292 T PL 09791292T PL 2328893 T3 PL2328893 T3 PL 2328893T3
Authority
PL
Poland
Prior art keywords
triazole compounds
hsp90 activity
modulate hsp90
modulate
activity
Prior art date
Application number
PL09791292T
Other languages
English (en)
Inventor
Weiwen Ying
Dinesh U Chimmanamada
Joseph A Burlison
Shijie Zhang
Minghu Song
Junghyun Chae
Original Assignee
Synta Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Pharmaceuticals Corp filed Critical Synta Pharmaceuticals Corp
Publication of PL2328893T3 publication Critical patent/PL2328893T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL09791292T 2008-08-08 2009-08-07 Związki triazolowe modulujące aktywność Hsp90 PL2328893T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18839708P 2008-08-08 2008-08-08
EP20090791292 EP2328893B1 (en) 2008-08-08 2009-08-07 Triazole compounds that modulate hsp90 activity
PCT/US2009/053157 WO2010017479A1 (en) 2008-08-08 2009-08-07 Triazole compounds that modulate hsp90 activity

Publications (1)

Publication Number Publication Date
PL2328893T3 true PL2328893T3 (pl) 2013-09-30

Family

ID=41172462

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09791292T PL2328893T3 (pl) 2008-08-08 2009-08-07 Związki triazolowe modulujące aktywność Hsp90

Country Status (7)

Country Link
US (1) US9126953B2 (pl)
EP (1) EP2328893B1 (pl)
DK (1) DK2328893T3 (pl)
ES (1) ES2415234T3 (pl)
PL (1) PL2328893T3 (pl)
PT (1) PT2328893E (pl)
WO (1) WO2010017479A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608635B2 (en) 2005-08-12 2009-10-27 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate HSP90 activity
US20070250391A1 (en) * 2006-04-05 2007-10-25 Prade Hendrik D Merchandising system and method for food and non-food items for a meal kit
AU2007267843B2 (en) 2006-05-25 2011-10-13 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
US8063083B2 (en) 2006-05-25 2011-11-22 Synta Pharmaceuticals Corp. Method for treating non-Hodgkin's lymphoma
WO2007139955A2 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
CA2653327A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate hsp90 activity and methods for identifying same
SI2035396T1 (sl) 2006-05-25 2014-08-29 Synta Pharmaceuticals Corp. Triazolne spojine, ki modulirajo aktivnost HSP90
ES2444695T3 (es) 2006-06-23 2014-02-26 Alethia Biotherapeutics Inc. Polinucleótidos y polipéptidos implicados en el cáncer
PL2118077T3 (pl) 2007-02-08 2015-05-29 Synta Pharmaceuticals Corp Związki triazolowe modulujące aktywność hsp90
US9156836B2 (en) * 2008-05-16 2015-10-13 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate HSP90 activity
US8450500B2 (en) 2008-06-04 2013-05-28 Synta Pharmaceuticals Corp. Pyrrole compounds that modulate HSP90 activity
US8648071B2 (en) 2008-06-27 2014-02-11 Synta Pharmaceuticals Corp. Hydrazonamide compounds that modulate Hsp90 activity
WO2010017545A2 (en) 2008-08-08 2010-02-11 Synta Pharamceuticals Corp. Triazole compounds that modulate hsp90 activity
CA2740900C (en) 2008-11-03 2019-09-24 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
DK2655345T3 (en) 2010-12-20 2015-05-04 Sigma Tau Res Switzerland Sa Aryltriazole Compounds with Anti-tumor Effect
SI3173427T1 (sl) 2011-03-31 2019-08-30 ADC Therapeutics SA, Protitelesa proti antigenu 1, povezanemu z ledvicami, in antigen vezavni fragmenti le-tega
CA2840986A1 (en) 2011-07-07 2013-01-10 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
CN102391260B (zh) * 2011-09-29 2014-12-10 上海交通大学 3-甲酮-6-取代-苯并呋喃类化合物及其制备方法和用途
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とhsp90阻害剤の組合せ療法
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors
KR102102239B1 (ko) 2012-01-09 2020-04-21 에이디씨 테라퓨틱스 에스에이 유방암을 치료하기 위한 방법
WO2015066053A2 (en) * 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
CN104447658A (zh) * 2014-12-04 2015-03-25 杭州杜易科技有限公司 一种卤代4-色满酮衍生物的制备方法
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
US11724997B2 (en) 2018-03-01 2023-08-15 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1817295B1 (en) * 2004-11-18 2012-11-07 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US7608635B2 (en) * 2005-08-12 2009-10-27 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate HSP90 activity
JP5118039B2 (ja) * 2005-08-18 2013-01-16 シンタ ファーマシューティカルズ コーポレーション Hsp90活性を調節するトリアゾール化合物
WO2007021877A1 (en) * 2005-08-18 2007-02-22 Synta Pharmaceuticals Corp. Imidazole compounds that modulate hsp90 activity
CA2653327A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate hsp90 activity and methods for identifying same
WO2007139955A2 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
SI2035396T1 (sl) * 2006-05-25 2014-08-29 Synta Pharmaceuticals Corp. Triazolne spojine, ki modulirajo aktivnost HSP90
EP2038262B1 (en) * 2006-05-25 2014-11-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US8063083B2 (en) * 2006-05-25 2011-11-22 Synta Pharmaceuticals Corp. Method for treating non-Hodgkin's lymphoma
AU2007267843B2 (en) * 2006-05-25 2011-10-13 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
WO2007139952A2 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for the preparation of triazole compounds with hsp90 modulating activity
AU2007284537B2 (en) * 2006-08-17 2012-04-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US20110046125A1 (en) * 2006-10-19 2011-02-24 Synta Pharmaceuticals Corp. Method for treating infections
WO2008057246A2 (en) * 2006-10-26 2008-05-15 Synta Pharmaceuticals Corp. Method for treating inflammatory disorders
PL2118077T3 (pl) 2007-02-08 2015-05-29 Synta Pharmaceuticals Corp Związki triazolowe modulujące aktywność hsp90
WO2008112199A1 (en) * 2007-03-12 2008-09-18 Synta Pharmaceuticals Corp. Method for inhibiting topoisomerase ii
EP2155694B1 (en) * 2007-03-27 2012-01-04 Synta Pharmaceuticals Corp. Triazinone and diazinone derivatives useful as hsp90 inhibitors
WO2008153730A2 (en) * 2007-05-25 2008-12-18 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with mutations in c-met
AU2008287367B2 (en) * 2007-08-13 2012-02-23 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US9156836B2 (en) * 2008-05-16 2015-10-13 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate HSP90 activity
US8450500B2 (en) * 2008-06-04 2013-05-28 Synta Pharmaceuticals Corp. Pyrrole compounds that modulate HSP90 activity
US8648071B2 (en) * 2008-06-27 2014-02-11 Synta Pharmaceuticals Corp. Hydrazonamide compounds that modulate Hsp90 activity
WO2010017545A2 (en) * 2008-08-08 2010-02-11 Synta Pharamceuticals Corp. Triazole compounds that modulate hsp90 activity
EP2490688B1 (en) * 2009-10-19 2014-10-08 Synta Pharmaceuticals Corp. Combination cancer therapy with hsp90 inhibitory compounds
EP2560640A1 (en) * 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
EP2560641A2 (en) * 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
WO2011146801A1 (en) * 2010-05-20 2011-11-24 Synta Pharmaceuticals Corp. Formulation and dosing of hsp90 inhibitory compounds
EP2575810A1 (en) * 2010-05-24 2013-04-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
US20130225870A1 (en) * 2010-08-25 2013-08-29 Synta Pharmaceuticals Corp. Method of synthesizing substituted 2-alkyl phenols
CN103269701A (zh) * 2010-09-13 2013-08-28 辛塔医药品有限公司 用于治疗野生型egfr和/或kras患者的非小细胞肺癌的hsp90抑制剂
US20140005145A1 (en) * 2010-12-08 2014-01-02 Synta Pharmaceuticals Corp. Combination breast cancer therapy with hsp90 inhibitory compounds
US20130331357A1 (en) * 2011-01-11 2013-12-12 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
WO2012116061A1 (en) * 2011-02-23 2012-08-30 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with radiotherapy
AU2012243289A1 (en) * 2011-02-24 2013-08-29 Synta Pharmaceuticals Corp. Prostate cancer therapy with Hsp90 inhibitory compounds
WO2012116247A1 (en) * 2011-02-25 2012-08-30 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
US8628752B2 (en) * 2011-10-28 2014-01-14 Synta Pharmaceuticals Corp. Methods of identifying HSP90 inhibitors with less ocular toxicity

Also Published As

Publication number Publication date
DK2328893T3 (da) 2013-06-17
WO2010017479A1 (en) 2010-02-11
EP2328893B1 (en) 2013-03-20
EP2328893A1 (en) 2011-06-08
US20110224206A1 (en) 2011-09-15
PT2328893E (pt) 2013-06-27
ES2415234T3 (es) 2013-07-24
US9126953B2 (en) 2015-09-08

Similar Documents

Publication Publication Date Title
PL2328893T3 (pl) Związki triazolowe modulujące aktywność Hsp90
ZA201001064B (en) Triazole compounds that modulate Hsp90 activity
IL200241A0 (en) Triazole compounds that modulate hsp90 activity
PT2035396E (pt) Compostos de triazol que modulam a atividade da hsp90
EP2141990A4 (en) ACTIVE COMPOUNDS ON 11BETA-HSD1
GB2463078B (en) Distributed storage
IL207757A0 (en) Hererocyclic compound
ZA201101410B (en) Insecticidal compounds
ZA201100804B (en) Insecticidal compounds
GB0807862D0 (en) Compounds
GB0800035D0 (en) Compounds
GB0812641D0 (en) Compounds
ZA201100139B (en) Azole compound
IL200165A0 (en) Compounds that inhibit cholinesterase
ZA201100032B (en) Triazole derivative or salt thereof
GB0816917D0 (en) Insect loading system
GB0801811D0 (en) Secure partitioning
HK1144820A (en) Triazole compounds that modulate hsp90 activity
GB0817982D0 (en) Compounds
GB0823484D0 (en) Insecticidal compounds
GB0813849D0 (en) Insecticidal compounds
GB0816133D0 (en) Insecticidal compounds
GB0819790D0 (en) Insecticidal compounds
GB0819791D0 (en) Insecticidal compounds
PL385082A1 (pl) Układ konserwujący do kosmetyków